Your browser doesn't support javascript.
loading
Connecting genomic and proteomic signatures of amyloid burden in the brain.
Puerta, Raquel; de Rojas, Itziar; García-González, Pablo; Olivé, Clàudia; Sotolongo-Grau, Oscar; García-Sánchez, Ainhoa; García-Gutiérrez, Fernando; Montrreal, Laura; Pablo Tartari, Juan; Sanabria, Ángela; Pytel, Vanesa; Lage, Carmen; Quintela, Inés; Aguilera, Nuria; Rodriguez-Rodriguez, Eloy; Alarcón-Martín, Emilio; Orellana, Adelina; Pastor, Pau; Pérez-Tur, Jordi; Piñol-Ripoll, Gerard; de Munian, Adolfo López; García-Alberca, Jose María; Royo, Jose Luís; Bullido, María Jesús; Álvarez, Victoria; Real, Luis Miguel; Anchuelo, Arturo Corbatón; Gómez-Garre, Dulcenombre; Larrad, María Teresa Martínez; Franco-Macías, Emilio; Mir, Pablo; Medina, Miguel; Sánchez-Valle, Raquel; Dols-Icardo, Oriol; Sáez, María Eugenia; Carracedo, Ángel; Tárraga, Lluís; Alegret, Montse; Valero, Sergi; Marquié, Marta; Boada, Mercè; Juan, Pascual Sánchez; Cavazos, Jose Enrique; Cabrera, Alfredo; Cano, Amanda.
Afiliación
  • Puerta R; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • de Rojas I; Universitat de Barcelona (UB).
  • García-González P; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Olivé C; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Sotolongo-Grau O; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • García-Sánchez A; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • García-Gutiérrez F; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Montrreal L; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Pablo Tartari J; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Sanabria Á; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Pytel V; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Lage C; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Quintela I; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Aguilera N; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Rodriguez-Rodriguez E; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Alarcón-Martín E; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Orellana A; Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.
  • Pastor P; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Pérez-Tur J; Grupo de Medicina Xenómica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCIII). Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
  • Piñol-Ripoll G; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • de Munian AL; Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.
  • García-Alberca JM; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Royo JL; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Bullido MJ; Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Spain.
  • Álvarez V; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Real LM; Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
  • Anchuelo AC; The Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
  • Gómez-Garre D; Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, Valencia, Spain.
  • Larrad MTM; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Franco-Macías E; Unidad Mixta de Neurologia Genètica, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
  • Mir P; Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain.
  • Medina M; Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain.
  • Sánchez-Valle R; Department of Neurology. Hospital Universitario Donostia. San Sebastian, Spain.
  • Dols-Icardo O; Department of Neurosciences. Faculty of Medicine and Nursery. University of the Basque Country, San Sebastián, Spain.
  • Sáez ME; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Carracedo Á; Neurosciences Area. Instituto Biodonostia. San Sebastian, Spain.
  • Tárraga L; Alzheimer Research Center & Memory Clinic, Andalusian Institute for Neuroscience, Málaga, Spain.
  • Alegret M; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Valero S; Departamento de Especialidades Quirúrgicas, Bioquímica e Inmunología. School of Medicine. University of Malaga. Málaga, Spain.
  • Marquié M; Centro de Biología Molecular Severo Ochoa (UAM-CSIC).
  • Boada M; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Juan PS; Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain.
  • Cavazos JE; Universidad Autónoma de Madrid.
  • Cabrera A; Laboratorio de Genética. Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Cano A; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA).
medRxiv ; 2024 Sep 06.
Article en En | MEDLINE | ID: mdl-39281766
ABSTRACT

Background:

Alzheimer's disease (AD) has a high heritable component characteristic of complex diseases, yet many of the genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may be helpful to understand the underlying biology of the disease.

Methods:

We performed a meta-analysis of GWAS of CSF Aß42 and PET measures combining six independent cohorts (n=2,076). Due to the opposite effect direction of Aß phenotypes in CSF and PET measures, only genetic signals in the opposite direction were considered for analysis (n=376,599). Polygenic risk scores (PRS) were calculated and evaluated for AD status and amyloid endophenotypes. We then searched the CSF proteome signature of brain amyloidosis using SOMAscan proteomic data (Ace cohort, n=1,008) and connected it with GWAS results of loci modulating amyloidosis. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n=13,409) and PET (n=13,116). This combined approach enabled the identification of overlapping genes and proteins associated with amyloid burden and the assessment of their biological significance using enrichment analyses.

Results:

After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and nine suggestive hits were annotated. We replicated the APOE loci using the large CSF-PET meta-GWAS and identified multiple AD-associated genes as well as the novel GADL1 locus. Additionally, we found a significant association between the AD PRS and amyloid levels, whereas no significant association was found between any Aß PRS with AD risk. CSF SOMAscan analysis identified 1,387 FDR-significant proteins associated with CSF Aß42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was very poor (n=35). The enrichment analysis of overlapping hits strongly suggested several signalling pathways connecting amyloidosis with the anchored component of the plasma membrane, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis.

Conclusions:

The strategy of combining CSF and PET amyloid endophenotypes GWAS with CSF proteome analyses might be effective for identifying signals associated with the AD pathological process and elucidate causative molecular mechanisms behind the amyloid mobilization in AD.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos